Mucopolysaccharidosis (MPS) Treatment Market

Market Insights on Mucopolysaccharidosis (MPS) Treatment covering sales outlook, demand forecast & up-to-date key trends

Mucopolysaccharidosis Treatment Market by Treatment Type (Enzyme Replacement Therapies and Stem Cell Therapies), Type of MPS (MPS I, MPS II, MPS IV A, MPS VI and MPS VII) & Region - Forecast 2022-2029

Request Sample Talk to Analyst

Mucopolysaccharidosis Treatment Market Outlook – 2022-2029

[220 Pages Report] The global Mucopolysaccharidosis Treatment Market is estimated to be worth around US$ 2.38 Bn in 2022. With increasing prevalence of mucopolysaccharidosis (MSP) worldwide, the overall market is projected to grow at a robust CAGR of 5.9% between 2022 and 2029, reaching a valuation of US$ 3.37 Bn by 2029.

Attribute	Details
Mucopolysaccharidosis treatment Market Estimated Size in 2022	US$ 2.38 Bn
Mucopolysaccharidosis treatment Market Projected Size in 2029	US$ 3.37 Bn
Mucopolysaccharidosis treatment Market Historical CAGR (2014-2021)	5.2 %
Mucopolysaccharidosis treatment Market Value-Based CAGR (2022-2029)	5.9%

MSP II segment will continue to dominate the mucopolysaccharidosis market, accounting for a share of 33.2% in 2022. Rising prevalence of MSP disorders along with growing adoption of mucopolysaccharidosis treatment for MSP II is boosting the market.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

How The Market Progressed Till June 2022?

Particulars	Details
H1, 2021	5.87%
H1, 2022 Projected	5.94%
H1, 2022 Outlook	5.44%
BPS Change - H1, 2022 (O) – H1, 2022 (P)	(-) 50 ↓
BPS Change – H1, 2022 (O) – H1, 2021	(-) 43 ↓

The comparative analysis and market growth rate of global mucopolysaccharides (MPS) treatment market has been studied by Future Market Insights. The global mucopolysaccharides (MPS) treatment market is predicted to drop by 43 Basis Share Point (BPS) in H1-2022 when compared to H1-2021, according to the FMI study.

Furthermore, the H1-2022 outlook and H1- 2022 projected growth rate showed declining variation in the BPS value by nearly 50 BPS. The fall in the BPS value for the mucopolysaccharides (MPS) treatment market can be attributed to the high cost of ERT and stem cell therapy treatment along with poor diagnosis rate and treatment rate in various emerging countries.

Regulatory compliances and clinical outcomes of treatment are dynamics which impact the market for mucopolysaccharides (MPS) treatment. The market is subject to be influenced by macro, regulatory, and industrial factors.

Furthermore, there has been an increase in the number of clinical trials in the recent time and thus, a huge number of pipeline products of many market players is estimated to flourish the market growth in the second half of the forecast period.

2014-2021 Mucopolysaccharidosis Treatment Market Outlook Compared to 2022-2029 Forecast

The global mucopolysaccharidosis treatment market is set to register a healthy CAGR of 5.9% between 2022 and 2029 in comparison to 5.2% CAGR registered from 2014 to 2021.

Rising health awareness, increasing prevalence of various forms of mucopolysaccharidosis worldwide, continuous advances in medical research and new drug launches and approvals are some of the factors driving the mucopolysaccharidosis treatment market.

Mucopolysaccharidosis is a group of inherited disorders in which the body is unable to breakdown glycosaminoglycan (long chains of sugars) due to absence or malfunctioning of certain enzymes. Presence of these disorders badly affects the physical and mental development of a person as well as damages the organs.

Although, there is no permanent cure for these disorders, mucopolysaccharidosis treatments such as enzyme replacement therapies and stem cell therapies can help to ease the symptoms.

Increasing prevalence of various type of mucopolysaccharidosis is a major force driving the global mucopolysaccharidosis treatment market. According to the National Organization for Rare Disorders (NORD), the total estimated prevalence of all forms of mucopolysaccharidosis is 1 in 25000 births.

Mucopolysaccharidosis (MPS) Treatment Market Download Report Brochure

Proper diagnosis of mucopolysaccharidosis is playing a vital role in expanding the growth of mucopolysaccharides treatment market. People with early diagnosis often opt for immediate treatment to relieve the symptoms and lead a normal life.

Key players operating in the market are continuously investing in research and development activities for new developing new therapeutics. Advances in stem cell therapies has provided a strong thrust to the mucopolysaccharidosis treatment market and the trend is likely to continue in the future.

Penetration of novel treatment approaches along with growing health awareness is anticipated to support the growth of mucopolysaccharidosis treatment market during the forecast period.

Spurred by aforementioned factors, the mucopolysaccharidosis treatment market is set to expand 1.4X through 2029.

How Will Focus on Clinical Trials Affect Mucopolysaccharidosis Treatment Market?

Clinical trials has remained the key focus of mucopolysaccharidosis treatment during the last few years. Amid rise in the cases of rare diseases, academic researchers, clinicians and leading market players are increasingly focusing on developing new treatment options that can significantly relieve the symptoms and help the patients to lead a normal life.

Increasing clinical research is in turn creating lucrative growth prospects within mucopolysaccharidosis treatment market and the trend is likely to continue in future.

Various regulatory bodies are approving the clinical trials of innovative treatments. For instance, in February 2020 – FDA granted fast track designation to Lysogene's LYS-SAF302 program for the treatment of MPS IIIA. Currently the new second generation gene therapy (LYS-SAF302) is being investigated in the international phase 2/3 clinical trial.

Similarly in Feb 2021, JCR Pharmaceuticals Co., Ltd. received clearance of its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to initiate a phase 3 clinical trial of JR-141 for the treatment of MPS II (Hunter syndrome) in the US.

Consistent clinical trials conducted to encourage the discovery of novel therapeutics is anticipated to expand the growth of mucopolysaccharidosis treatment market during the forecast period.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What will be the Key Restraints to Mucopolysaccharidosis Treatment Market Growth?

One of the major factors restraining the growth of mucopolysaccharidosis treatment market is the high cost associated with mucopolysaccharidosis treatment. Both ERT and stem cell therapies treatment are expensive. As a result, a large section population are not able to afford advanced treatments.

Moreover, lack of favorable reimbursement policies across and poor health awareness are limiting the growth of the market.

Country-wise Insights

What is driving the U.S. Mucopolysaccharidosis Treatment Market?

“Drug Development and Approvals to Spur the U.S. Market Growth”

As per FMI, the U.S. will continue to dominate the North America mucopolysaccharidosis treatment market during the forecast period. The U.S. mucopolysaccharides treatment market is driven by rising awareness, new drug approvals, presence of favorable reimbursement policies, well established healthcare infrastructure and presence of leading market players.

The U.S. is one of the most advanced nations in the world. It is home to some of the leading pharmaceutical companies. Advancements in medical research has enabled the market players to develop innovative products with effective features. New treatments are being continuously introduced to counter the burden of rare diseases. This is, in turn triggering the growth of mucopolysaccharides treatment market.

Presence of regulatory bodies such as the U.S Food and Drug Administration (FDA) is playing a key role in expanding the U.S. mucopolysaccharidosis treatment market. Various steps are being taken to foster the drug development for rare diseases.

For instance, in February 2020, FDA issued a draft guidance regarding the rare disease, Sanofilippo syndrome. The draft is aimed to support the development of therapies for MPS III (Sanfilippo syndrome)

Moreover, the rise in the cases of mucopolysaccharidosis coupled with increasing diagnostic screening is positively impacting the growth of the U.S. mucopolysaccharidosis treatment market. According to an article published in the Orphanet Journal of Rare Diseases, prevalence of MPS in the U.S. is around 2.67 per 1 million.

Amid intensifying clinical trials, a healthy share has been projected for the U.S. mucopolysaccharides treatment market by 2029.

Why is Japan Emerging as One of the Global Leaders in Mucopolysaccharidosis Treatment Market?

“Focus on Clinical Trials Presenting Attractive Growth Prospects in Japan”

Japan boasts the presence of advanced healthcare system. The government in Japan spends increasingly on developing healthcare infrastructure to accommodate the nation’s healthcare needs in the most efficient manner possible.

Over the last few decades, there has been an increase in the cases of mucopolysaccharidosis disorders. This has triggered the growth of mucopolysaccharidosis treatment market in the country.

Various novel treatments such as hunterase are being introduced in Japan to help the patients suffering from genetic MPS disorders. Moreover, various clinical trials are being conducted to find new and effective treatments for various type of mucopolysaccharidosis disorders.

For instance, in 2021, JCR Pharmaceuticals initiated a phase 3 clinical trial of JR-141 for the treatment of hunter syndrome.

What are the Growth Projections for the U.K. Market?

“Rising Investments in Medical Research to Present Attractive Prospects for Growth in the U.K.”

As per FMI, the U.K. mucopolysaccharidosis treatment market is poised to exhibit strong growth during the forecast period. Increasing government support, rising prevalence of rare disorders and increasing investments in medical research are some of the factors driving the U.K. mucopolysaccharidosis treatment market.

The U.K. government spends millions of dollars on medical research annually. According to the National Institute for Health Research (NIHR), around € 4.5 billion was invested in the U.K. health research projects in 2018. This is positively impacting the market growth across the country.

Moreover, growing popularity of stem cell therapies for the effective treatment of various type of mucopolysaccharidosis will continue to accelerate the growth of the market during the forecast period from 2022 and 2029.

Category-wise Insights

Which is the Most Preferred Treatment for Mucopolysaccharidosis?

“Enzyme Replacement Therapy (ERT) Remains the Gold Standard Treatment for Mucopolysaccharidosis”

Based on treatment, mucopolysaccharidosis treatment market is segmented into enzyme replacement therapies (ERT) and stem cell therapies. Among these two, enzyme replacement therapies segment dominates the mucopolysaccharidosis treatment market.

ERT remains the primary treatment option for mucopolysaccharidosis across the globe. Easy availability and continuous approvals remain the key factors fueling the adoption of enzymes replacement therapies for relieving the symptoms of mucopolysaccharidosis.

Enzyme replacement therapies replace or generate the deficient enzyme and thus effectively helps to treat the condition. Drugs such as aldurazyme, naglazyme, vimizim, elaprase, mepsevii and hunterase are being consumed on large scales for the treatment of mucopolysaccharides.

Which Type of MSP Dominates the Mucopolysaccharidosis Treatment Market?

“MPS II Segment to Continue Accounting for Maximum Sales”

In terms of MPS type, the mucopolysaccharidosis treatment has been segmented into MPS I, MPS II, MPS IV A, MPS VI and MPS VII. Among these, MPS II (Hunter syndrome) segment dominates the global mucopolysaccharidosis treatment market, accounting for the largest share of 33.2% in 2022.

MPS II or hunter syndrome is a rare inherited genetic disorder caused by absence or malfunctioning of enzyme 2-sulfatas. Absence of this enzyme causes permanent progressive damage affecting mental development, appearance and organ functions. As a result, medical products such as hunterase and elaprase are being consumed to relieve the symptoms.

Increasing prevalence of MPS II coupled with presence of multiple treatment options is triggering the growth of MPS II segment and the trend is likely to continue in the future.

Who is the Leading End User of Mucopolysaccharidosis Treatment?

“Favorable Scenario Enables Dominance of Hospitals Segment”

In terms of end user, the global donor egg IVF market is segmented into hospital, specialty clinics, medical research centers and home-infusion.

Among these, the hospitals segment accounts for major revenue share in the global mucopolysaccharides treatment market in 2022. Presence of trained medical professionals and low-cost treatment are some of the factors prompting patients to opt for mucopolysaccharidosis treatment in hospitals.

Hospitals are expected to remain the only means of accessing the treatment for maximum number of people living in developing and underdeveloped regions. However, specialty clinics and home infusion segments are anticipated to grow at a robust CAGR over the forecast period.

Competitive Landscape

Leading players operating in mucopolysaccharidosis treatment market are vigorously investing in research and development activities. They are adopted various organic and inorganic growth strategies such as mergers, new product launches and approvals, partnerships and acquisitions to gain a competitive edge in the market.

In March 2021, JCR Pharmaceuticals Co., Ltd. announced that the approval of IZCARGO (pabinafusp alfa 10 mL, intravenous drip infusion) by Ministry of Health, Labour and Welfare (MHLW) for the treatment of mucopolysaccharidosis type II (MPS II, or Hunter syndrome).
In September 2021, Takeda collaborated with JCR Pharmaceutical to commercialize the next generation hunter syndrome therapy (JR-141) outside the U.S.
In July 2020, Lysogene collaborated with the Weizmann Institute of Science with the aim of developing a novel AAV gene therapy approach for various genetic disorders.
In September 2020, REGENXBIO Inc., a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, expanded its RGX-121 program for the treatment of Mucopolysaccharidosis Type II.
In November 2017, the U.S. Food and Drug Administration (FDA) approved Mepsevii for the treatment of Sly syndrome (MPS VII) in pediatric and adult persons.

Scope of the Report

Attribute	Details
Historical Data Available for	2014-2021
Forecast Period	2022-2029
Market Analysis	Units for Volume and US$ Mn for Value
Key Regions Covered	North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East & Africa
Key Countries Covered	US, Canada, Mexico, Brazil, Germany, U.K., France, Italy, Spain, Russia, Poland, China, Japan, South Korea, India, ASEAN, Turkey and South Africa
Key Segments Covered	Cycle Type, End Use and Region
Key Companies Profiled	BioMarin Takeda Pharmaceutical Company Limited Sanofi S.A. Ultragenyx Pharmaceutical Inc. Sangamo Therapeutics, Inc. REGENXBIO Inc. Sarepta Therapeutics Abeona Therapeutics, Inc.
Report Coverage	Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives
Customization & Pricing	Available upon Request

Mucopolysaccharidosis Treatment Market by Category

Treatment:

Enzyme Replacement Therapies
Stem Cell Therapies
- Bone Marrow Transplantation
- Umbilical Cord Blood Transplantation

Type of MPS:

MPS I
MPS II
MPS IV A
MPS VI
MPS VII

End User:

Hospital
Specialty Clinics
Medical Research Centers
Home-infusion

Frequently Asked Questions

What is the current mucopolysaccharidosis treatment market valuation?

The mucopolysaccharidosis treatment market is estimated to be worth around US$ 2.34 Bn in 2022.

What is the mucopolysaccharidosis treatment market demand outlook?

As per FMI, the mucopolysaccharidosis treatment market is forecast to register a steady CAGR of 5.9% between 2022 and 2029

At what rate did the mucopolysaccharidosis treatment market grow between 2014 and 2021?

The mucopolysaccharidosis treatment market grew at a CAGR of 5.2% between 2014 and 2021.

What are the key trends shaping the mucopolysaccharidosis treatment market?

Continuous drug approvals, increasing government initiatives to tackle the burden of rare diseases and rising penetration of novel treatments across developing economies are some of the key trends shaping the growth of mucopolysaccharidosis treatment market.

Who are the leading players in mucopolysaccharidosis treatment market?

BioMarin, Takeda Pharmaceutical Company Limited, Sanofi S.A., and Ultragenyx Pharmaceutical Inc. BioMarin, Sangamo Therapeutics, Inc., REGENXBIO Inc., Sarepta Therapeutics, Abeona Therapeutics, Inc. are some of the leading players operating in the mucopolysaccharidosis treatment market.

Table of Content

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply Side Trends

1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Technological Developments

4. Key Success Factors

4.1. Regulatory Scenario

4.2. Pipeline Analysis

4.3. Snapshot of Developments for Mucopolysaccharidosis Type 3

4.4. Designed Designation

4.5. Rare Disease Framework

5. Global Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast, 2022-2029

5.1. Historical Market Value (US$ Mn) Analysis, 2014-2021

5.2. Current and Future Market Value (US$ Mn) Projections, 2022-2029

5.2.1. Y-o-Y Growth Trend Analysis

5.2.2. Absolute $ Opportunity Analysis

6. Market Background

6.1. Macro-Economic Factors

6.1.1. Global GDP Growth Outlook

6.1.2. Global Healthcare Expenditure Outlook

6.2. Forecast Factors - Relevance & Impact

6.2.1. Improved Services in Concerned Economies

6.2.2. Drug Candidates in Pipeline

6.2.3. Drug Approval Process in Different Economies

6.2.4. Growth in Production Capacity

6.2.5. Change in Cost of Treatment

6.3. Market Dynamics

6.3.1. Drivers

6.3.2. Restraints

6.3.3. Opportunity Analysis

7. Global Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, by Treatment Type

7.1. Introduction / Key Findings

7.2. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2014 - 2021

7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Treatment Type, 2022 - 2029

7.3.1. Enzyme Replacement Therapies

7.3.2. Stem Cell Therapies

7.3.2.1. Bone Marrow Transplantation (BMT)

7.3.2.2. Umbilical Cord Blood Transplantation (UCBT)

7.4. Market Attractiveness Analysis By Treatment Type

8. Global Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, by Type of MPS

8.1. Introduction / Key Findings

8.2. Historical Market Size (US$ Mn) Analysis By Type of MPS, 2014 - 2021

8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Type of MPS, 2022 - 2029

8.3.1. MPS I

8.3.2. MPS II

8.3.3. MPS IV A

8.3.4. MPS VI

8.3.5. MPS VII

8.4. Market Attractiveness Analysis By Type of MPS

9. Global Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, by End User

9.1. Introduction / Key Findings

9.2. Historical Market Size (US$ Mn) Analysis By End User, 2014 - 2021

9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2022 - 2029

9.3.1. Hospital

9.3.2. Specialty Clinics

9.3.3. Medical Research Centers

9.3.4. Home-infusion

9.4. Market Attractiveness Analysis By End User

10. Global Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, by Region

10.1. Introduction

10.2. Historical Market Size (US$ Mn) Analysis By Region, 2014 - 2021

10.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022 - 2029

10.3.1. North America

10.3.2. Latin America

10.3.3. Europe

10.3.4. East Asia

10.3.5. South Asia

10.3.6. MEA

10.3.7. Oceania

10.4. Market Attractiveness Analysis By Region

11. North America Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029

11.1. Introduction

11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2021

11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2029

11.3.1. By Country

11.3.1.1. U.S.

11.3.1.2. Canada

11.3.2. By Treatment Type

11.3.3. By Type of MPS

11.3.4. By End User

11.4. Market Attractiveness Analysis

12. Latin America Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029

12.1. Introduction

12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2021

12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2029

12.3.1. By Country

12.3.1.1. Brazil

12.3.1.2. Mexico

12.3.1.3. Argentina

12.3.1.4. Rest of Latin America

12.3.2. By Treatment Type

12.3.3. By Type of MPS

12.3.4. By End User

12.4. Market Attractiveness Analysis

13. Europe Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029

13.1. Introduction

13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2021

13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2029

13.3.1. By Country

13.3.1.1. Germany

13.3.1.2. Italy

13.3.1.3. France

13.3.1.4. U.K.

13.3.1.5. Spain

13.3.1.6. BENELUX

13.3.1.7. Russia

13.3.1.8. Rest of Europe

13.3.2. By Treatment Type

13.3.3. By Type of MPS

13.3.4. By End User

13.4. Market Attractiveness Analysis

14. South Asia Hysteroscopy Systems Market Analysis 2014-2021 and Forecast 2022-2029

14.1. Introduction

14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2021

14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2029

14.3.1. By Country

14.3.1.1. India

14.3.1.2. Thailand

14.3.1.3. Indonesia

14.3.1.4. Malaysia

14.3.1.5. Rest of South Asia

14.3.2. By Treatment Type

14.3.3. By Type of MPS

14.3.4. By End User

14.4. Market Attractiveness Analysis

15. East Asia Hysteroscopy Systems Market Analysis 2014-2021 and Forecast 2022-2029

15.1. Introduction

15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2021

15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2029

15.3.1. By Country

15.3.1.1. China

15.3.1.2. Japan

15.3.1.3. South Korea

15.3.2. By Treatment Type

15.3.3. By Type of MPS

15.3.4. By End User

15.4. Market Attractiveness Analysis

16. Oceania Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029

16.1. Introduction

16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2021

16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2029

16.3.1. By Country

16.3.1.1. Australia

16.3.1.2. New Zealand

16.3.2. By Treatment Type

16.3.3. By Type of MPS

16.3.4. By End User

16.4. Market Attractiveness Analysis

17. Middle East and Africa Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029

17.1. Introduction

17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2014 - 2021

17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022 - 2029

17.3.1. By Country

17.3.1.1. GCC Countries

17.3.1.2. South Africa

17.3.1.3. Rest of Middle East and Africa

17.3.2. By Treatment Type

17.3.3. By Type of MPS

17.3.4. By End User

17.4. Market Attractiveness Analysis

18. Market Structure Analysis

18.1. Market Share Analysis

18.2. Competition Mapping

19. Competition Analysis

19.1. Company Dashboard

19.2. Company Profile

19.2.1. Sanofi S.A.

19.2.1.1. Overview

19.2.1.2. Service Portfolio

19.2.1.3. Analyst Commentary

19.2.2. Shire

19.2.3. BioMarin Pharmaceutical Inc.

19.2.4. Ultragenyx Pharmaceutical Inc.

19.2.5. Sarepta Therapeutics

19.2.6. Abeona Therapeutics, Inc.

19.2.7. ArmaGen

19.2.8. Eloxx Pharmaceuticals

19.2.9. Esteve

19.2.10. Immusoft Corporation

19.2.11. Inventiva

19.2.12. Orchard Therapeutics Limited

19.2.13. REGENXBIO Inc.

19.2.14. Sangamo Therapeutics, Inc.

20. Assumptions and Acronyms Used

21. Research Methodology

List of Tables

Table 01: Comparison of orphan drug regulation across the US, Europe, Japan, Korea, Taiwan and China, 2017

Table 02:  Snapshot of Developments for Mucopolysaccharidosis Type 3

Table 03: Snapshot of Developments for Mucopolysaccharidosis Type 3 

Table 04: Global Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Treatment Type

Table 05: Global Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Type of Mucopolysaccharidosis (MPS) 

Table 06: Global Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By End User

Table 07: Global Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Region

Table 08: North America Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Country

Table 09: North America Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Treatment Type

Table 10: North America Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Type of MPS

Table 11: North America Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By End User

Table 12: Latin America Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Country

Table 13: Latin America Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Treatment Type

Table 14: Latin America Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Type of MPS

Table 15: Latin America Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By End User

Table 16: Europe Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Country

Table 17: Europe Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Treatment Type

Table 18: Europe Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Type of MPS

Table 19: Europe Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By End User

Table 20: South Asia Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Country

Table 21: South Asia Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Treatment Type

Table 22: South Asia Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Type of MPS

Table 23: South Asia Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By End User

Table 24: East Asia Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Country

Table 25: East Asia Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Treatment Type

Table 26: East Asia Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Type of MPS

Table 27: East Asia Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By End User

Table 28: Oceania Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Country

Table 29: Oceania Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Treatment Type

Table 30: Oceania Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Type of MPS

Table 31: Oceania Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By End User

Table 32: MEA Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Country

Table 33: MEA Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Treatment Type

Table 34: MEA Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Type of MPS

Table 35: MEA Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By End User

Table 36: India Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Treatment Type

Table 37: India Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Type of MPS

Table 38: India Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By End User

Table 39: Brazil Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Treatment Type

Table 40: Brazil Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Type of MPS

Table 41: Brazil Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By End User

Table 42: South Korea Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Treatment Type

Table 43: South Korea Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By Type of MPS

Table 44: South Korea Mucopolysaccharidosis Treatment Market Analysis 2014-2021 and Forecast 2022-2029, By End User

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Pipeline Assessment For Mucopolysaccharidosis Treatment, By phase

Figure 02: Pipeline Assessment For Mucopolysaccharidosis Treatment, By Study Type

Figure 03: Global Mucopolysaccharidosis Treatment Market Value Analysis and Forecast, 2021–2029 (US$ Mn)

Figure 04: Global Mucopolysaccharidosis Treatment Market Absolute $ Opportunity (US$ Mn), 2014–2021

Figure 05: Global Mucopolysaccharidosis Treatment Market Absolute $ Opportunity (US$ Mn), 2022-2029

Figure 06: Global Mucopolysaccharidosis Treatment Market US$ Mn, by Treatment Type

Figure 07: Global Mucopolysaccharidosis Treatment Market Share%, by Treatment Type, 2019E

Figure 08: Global Mucopolysaccharidosis Treatment Market Share%, by Treatment Type, 2029F

Figure 09: Global Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Treatment Type

Figure 10: Global Mucopolysaccharidosis Treatment Market US$ Mn, by Type of MPS

Figure 11: Global Mucopolysaccharidosis Treatment Market Share%, by Type of MPS, 2019E

Figure 12: Global Mucopolysaccharidosis Treatment Market Share%, by Type of MPS, 2029F

Figure 13: Global Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Type of MPS

Figure 14: Global Mucopolysaccharidosis Treatment Market US$ Mn, by End User

Figure 15: Global Mucopolysaccharidosis Treatment Market Share%, by End User, 2019E

Figure 16: Global Mucopolysaccharidosis Treatment Market Share%, by End User, 2029F

Figure 17: Global Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By End User

Figure 18: Global Mucopolysaccharidosis Treatment Market US$ Mn, by Region

Figure 19: Global Mucopolysaccharidosis Treatment Market Share%, by Region, 2019E

Figure 20: Global Mucopolysaccharidosis Treatment Market Share%, by Region, 2029F

Figure 21: Global Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Region

Figure 22: North America Mucopolysaccharidosis Treatment Market Value Share (2018A), By Country

Figure 23: North America Mucopolysaccharidosis Treatment Market Value Share Comparison for 2018A and 2029F, By Treatment Type, Type of Mucopolysaccharidosis and End user

Figure 24: North America Mucopolysaccharidosis Treatment Market size (US$ Mn) Analysis, 2014–2021

Figure 25: North America Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 26: US Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 27: US Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 28: Canada Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 29: Canada Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 30: North America Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021, by Enzyme Replacement Therapies

Figure 31: North America Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029, by Enzyme Replacement Therapies

Figure 32: North America Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021, by Stem Cell Therapies

Figure 33: North America Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029, by Stem Cell Therapies

Figure 34: North America Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Treatment Type

Figure 35: North America Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By End User

Figure 36: North America Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Type Of MPS

Figure 37: North America Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Country

Figure 38: Latin America Mucopolysaccharidosis Treatment Market Value Share (2018A), By Country

Figure 39: Latin America Mucopolysaccharidosis Treatment Market Value Share Comparison for 2018A and 2029F, By Treatment Type, Type of Mucopolysaccharidosis and End user

Figure 40: Latin America Mucopolysaccharidosis Treatment Market size (US$ Mn) Analysis, 2014–2021

Figure 41: Latin America Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 42: Brazil Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 43: Brazil Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 44: Mexico Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 45: Mexico Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 46: Rest of Latin America Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 47: Rest of Latin America Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 48: Latin America Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021, by Enzyme Replacement Therapies

Figure 49: Latin America Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029, by Enzyme Replacement Therapies

Figure 50: Latin America Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021, by Stem Cell Therapies

Figure 51: Latin America Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029, by Stem Cell Therapies

Figure 52: Latin America Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Treatment Type

Figure 53: Latin America Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By End User

Figure 54: Latin America Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Type Of MPS

Figure 55: Latin America Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Country

Figure 56: Europe Mucopolysaccharidosis Treatment Market Value Share (2018A), By Country

Figure 57: Europe Mucopolysaccharidosis Treatment Market Value Share Comparison for 2018A and 2029F, By Treatment Type, Type of Mucopolysaccharidosis and End user

Figure 58: Europe Mucopolysaccharidosis Treatment Market size (US$ Mn) Analysis, 2014–2021

Figure 59: Europe Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 60: U.K. Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 61: U.K. Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 62: Germany Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 63: Germany Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 64: France Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 65: France Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 66: Italy Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 67: Italy Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 68: Spain Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 69: Spain Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 70: BENELUX Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 71: BENELUX Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 72: Russia Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 73: Russia Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 74: Rest of Europe Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 75: Rest of Europe Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 76: Europe Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021, by Enzyme Replacement Therapies

Figure 77: Europe Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029, by Enzyme Replacement Therapies

Figure 78: Europe Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021, by Stem Cell Therapies

Figure 79: Europe Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029, by Stem Cell Therapies

Figure 80: Europe Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Treatment Type

Figure 81: Europe Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By End User

Figure 82: Europe Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Type Of MPS

Figure 83: Europe Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Country

Figure 84: South Asia Mucopolysaccharidosis Treatment Market Value Share (2018A), By Country

Figure 85: South Asia Mucopolysaccharidosis Treatment Market Value Share Comparison for 2018A and 2029F, By Treatment Type, Type of Mucopolysaccharidosis and End user

Figure 86: South Asia Mucopolysaccharidosis Treatment Market size (US$ Mn) Analysis, 2014–2021

Figure 87: South Asia Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 88: India  Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 89: India  Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 90: Thailand Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 91: Thailand Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 92: Indonesia  Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 93: Indonesia Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 94: Malaysia Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 95: Malaysia Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 96: Rest of South Asia Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 97: Rest of South Asia Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 98: South Asia Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021, by Enzyme Replacement Therapies

Figure 99: South Asia Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029, by Enzyme Replacement Therapies

Figure 100: South Asia Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021, by Stem Cell Therapies

Figure 101: South Asia Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029, by Stem Cell Therapies

Figure 102: South Asia Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Treatment Type

Figure 103: South Asia Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By End User

Figure 104: South Asia Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Type Of MPS

Figure 105: South Asia Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Country

Figure 106: East Asia Mucopolysaccharidosis Treatment Market Value Share (2018A), By Country

Figure 107: East Asia Mucopolysaccharidosis Treatment Market Value Share Comparison for 2018A and 2029F, By Treatment Type, Type of Mucopolysaccharidosis and End user

Figure 108: East Asia Mucopolysaccharidosis Treatment Market size (US$ Mn) Analysis, 2014–2021

Figure 109: East Asia Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 110: China Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 111: China Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 112: Japan Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 113: Japan Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 114: South Korea Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 115: South Korea Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 116: East Asia Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021, by Enzyme Replacement Therapies

Figure 117: East Asia Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029, by Enzyme Replacement Therapies

Figure 118: East Asia Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021, by Stem Cell Therapies

Figure 119: East Asia Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029, by Stem Cell Therapies

Figure 120: East Asia Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Treatment Type

Figure 121: East Asia Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By End User

Figure 122: East Asia Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Type Of MPS

Figure 123: East Asia Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Country

Figure 124: Oceania Mucopolysaccharidosis Treatment Market Value Share (2018A), By Country

Figure 125: Oceania Mucopolysaccharidosis Treatment Market Value Share Comparison for 2018A and 2029F, By Treatment Type, Type of Mucopolysaccharidosis and End user

Figure 126: Oceania Mucopolysaccharidosis Treatment Market size (US$ Mn) Analysis, 2014–2021

Figure 127: Oceania Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 128: Australia Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 129: Australia Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 130: New Zealand Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 131: New Zealand Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 132: Oceania Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021, by Enzyme Replacement Therapies

Figure 133: Oceania Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029, by Enzyme Replacement Therapies

Figure 134: Oceania Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021, by Stem Cell Therapies

Figure 135: Oceania Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029, by Stem Cell Therapies

Figure 136: Oceania Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Treatment Type

Figure 137: Oceania Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By End User

Figure 138: Oceania Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Type Of MPS

Figure 139: Oceania Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Country

Figure 140: MEA Mucopolysaccharidosis Treatment Market Value Share (2018A), By Country

Figure 141: MEA Mucopolysaccharidosis Treatment Market Value Share Comparison for 2018A and 2029F, By Treatment Type, Type of Mucopolysaccharidosis and End user

Figure 142: MEA Mucopolysaccharidosis Treatment Market size (US$ Mn) Analysis, 2014–2021

Figure 143: MEA Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 144: South Africa Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 145: South Africa Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 146: GCC Countries Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 147: GCC Countries Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 148: Rest of MEA Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 149: Rest of MEA Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021

Figure 150: MEA Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021, by Enzyme Replacement Therapies

Figure 151: MEA Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029, by Enzyme Replacement Therapies

Figure 152: MEA Mucopolysaccharidosis Treatment Market Size (US$ Mn) Analysis, 2014–2021, by Stem Cell Therapies

Figure 153: MEA Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029, by Stem Cell Therapies

Figure 154: MEA Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Treatment Type

Figure 155: MEA Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By End User

Figure 156: MEA Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Type Of MPS

Figure 157: MEA Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Country

Figure 158: Mucopolysaccharidosis Treatment Market Value Proportion Analysis, By Key Countries, 2019E

Figure 159: Global Vs. Country, Y-O-Y Growth Comparison

Figure 160: India Mucopolysaccharidosis Treatment Market size (US$ Mn) Analysis, 2014–2021

Figure 161: India Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 162: India Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Treatment Type

Figure 163: India Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Type Of MPS

Figure 164: India Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By End User

Figure 165: Brazil Mucopolysaccharidosis Treatment Market size (US$ Mn) Analysis, 2014–2021

Figure 166: Brazil Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 167: Brazil Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Treatment Type

Figure 168: Brazil Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Type Of MPS

Figure 169: Brazil Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By End User

Figure 170: South Korea Mucopolysaccharidosis Treatment Market size (US$ Mn) Analysis, 2014–2021

Figure 171: South Korea Mucopolysaccharidosis Treatment Market Value (US$ Mn) & Y-o-Y Growth (%), 2022–2029

Figure 172: South Korea Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Treatment Type

Figure 173: South Korea Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By Type Of MPS

Figure 174: South Korea Mucopolysaccharidosis Treatment Market Attractiveness Analysis, By End